EZH2 and non-small cell lung carcinoma: Notably, enzymes such as EZH2 and PRMT5 emerge as master regulators, hijacking non-coding RNAs (e.g., LINC00665, ACTA2-AS1), rewiring oncogenic pathways (e.g., PI3K/AKT, Wnt/β-catenin), and sculpting immunosuppressive microenvironments to confer survival advantages to NSCLC cells.